What Are the Defense Standards for Products Liability Litigation?

Pharmaceutical companies operate under dual accountability: FDA oversight during pre-market approval and post-market surveillance, and state tort law governing product liability claims. These regimes do not always align. A drug may receive FDA approval based on a favorable risk-benefit analysis at the time of marketing, yet later clinical experience or epidemiological studies may reveal risks that plaintiffs argue should have triggered a design change or enhanced warnings.

Courts recognize that FDA approval carries significant weight in product liability defense, but approval is not a complete bar to liability. New York courts, like many state jurisdictions, apply the principle that products liability claims may proceed even where a pharmaceutical product complied with FDA requirements at the time of approval. The critical distinction lies in whether the manufacturer had a duty to communicate emerging safety information or modify the product formulation based on post-approval data. This creates a moving target for corporate risk management: what was adequate disclosure in year one may become inadequate by year five if new adverse event reports accumulate.

Pharmaceutical design defect claims require proof that the product's formulation or chemical composition created an unreasonable risk of harm, and that a feasible alternative design existed. Failure-to-warn claims allege that the manufacturer did not adequately communicate known risks to prescribers or, in some cases, to patients. These are distinct legal theories with different causation burdens. A corporate defendant must differentiate its defense strategy depending on which theory a plaintiff pursues.

Design defect in the pharmaceutical context often fails unless the plaintiff can demonstrate that the drug's therapeutic benefit did not justify its risks at the time of marketing or that a safer formulation was available and feasible. Courts recognize the risk-benefit calculus inherent in drug approval: a medication for a serious illness may carry significant side effects, yet still be approvable and non-defective. Failure-to-warn claims, by contrast, focus on the adequacy of communication. Even if a design defect claim fails, a manufacturer may face liability if it failed to disclose known risks in the package insert or in communications to healthcare providers.

Pharmaceutical companies cannot eliminate product liability exposure, but they can manage litigation risk through disciplined documentation and early legal engagement. The corporate record—including safety meeting minutes, adverse event summaries, regulatory submissions, and communications with healthcare providers—becomes the evidentiary foundation for defense or plaintiff's offense. Companies that maintain clear, contemporaneous records of safety reviews and risk-benefit assessments demonstrate that they took known risks seriously. Conversely, gaps in documentation, destroyed records, or evidence of delayed reporting invite adverse inferences and increase settlement pressure.

From a corporate governance standpoint, establishing a robust pharmacovigilance function and ensuring that safety data flows promptly to regulatory and legal teams reduces the likelihood of missed opportunities to update labeling or communicate emerging risks. When adverse events accumulate, the failure to escalate or act on that data becomes a liability multiplier. A single adverse event report may not trigger a label change, but a pattern of similar events that the manufacturer did not aggregate or report compounds exposure. Early involvement of counsel in safety review meetings ensures that legal privilege protections apply to internal risk assessments and that the company's decision-making process is documented in a way that supports later defense.

The landscape of pharmaceutical liability continues to evolve. Recent trends include increased scrutiny of off-label marketing, heightened focus on pediatric and geriatric safety data, and growing plaintiff success in failure-to-warn cases where manufacturers had internal knowledge of risks but did not promptly update labeling. Companies must stay attuned to regulatory guidance from the FDA on label changes and safety communications, as courts often treat FDA guidance as a baseline standard for manufacturer conduct.

Looking forward, corporate defendants should prioritize several concrete evaluations: first, conduct a systematic audit of all adverse event reports received in the past five years and assess whether any pattern of events should have triggered a label update or safety communication; second, review internal safety meeting minutes to identify whether any safety signal was discussed but not acted upon, and document the rationale for any decision to delay or forgo corrective action; third, ensure that all regulatory submissions to the FDA, including annual reports and adverse event summaries, are complete and timely, and that any discrepancies between internal safety data and regulatory filings are resolved before litigation discovery begins. These steps do not guarantee favorable outcomes, but they establish a factual record that demonstrates the company took product safety seriously and acted on known risks in a timely manner. In pharmaceutical litigation, the company that can point to a disciplined, documented decision-making process often fares better than one whose internal record appears reactive or incomplete.